LifeMD, Inc. (LFMD) got here out with a quarterly lack of $0.1 per share versus the Zacks Consensus Estimate of a lack of $0.06. This compares to a lack of $0.14 per share a yr in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of -66.67%. 1 / 4 in the past, it was anticipated that this firm would put up a lack of $0.02 per share when it really produced a lack of $0.06, delivering a shock of -200%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates two occasions.
LifeMD, which belongs to the Zacks Medical Companies business, posted revenues of $60.17 million for the quarter ended September 2025, lacking the Zacks Consensus Estimate by 3.42%. This compares to year-ago revenues of $53.39 million. The corporate has topped consensus income estimates two occasions over the past 4 quarters.
The sustainability of the inventory’s rapid worth motion based mostly on the recently-released numbers and future earnings expectations will largely rely on administration’s commentary on the earnings name.
LifeMD shares have misplaced about 6.5% for the reason that starting of the yr versus the S&P 500’s achieve of 14.5%.
What’s Subsequent for LifeMD?
Whereas LifeMD has underperformed the market up to now this yr, the query that involves buyers’ minds is: what’s subsequent for the inventory?
There aren’t any simple solutions to this key query, however one dependable measure that may assist buyers handle that is the corporate’s earnings outlook. Not solely does this embrace present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified these days.
Empirical analysis reveals a powerful correlation between near-term inventory actions and traits in earnings estimate revisions. Traders can monitor such revisions by themselves or depend on a tried-and-tested score software just like the Zacks Rank, which has a formidable monitor report of harnessing the facility of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions development for LifeMD was combined. Whereas the magnitude and course of estimate revisions may change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out in keeping with the market within the close to future. You possibly can see the whole checklist of at this time’s Zacks #1 Rank (Sturdy Purchase) shares right here.
It is going to be fascinating to see how estimates for the approaching quarters and the present fiscal yr change within the days forward. The present consensus EPS estimate is -$0.05 on $62.85 million in revenues for the approaching quarter and -$0.15 on $253.06 million in revenues for the present fiscal yr.
Traders ought to be aware of the truth that the outlook for the business can have a cloth influence on the efficiency of the inventory as effectively. By way of the Zacks Business Rank, Medical Companies is at the moment within the backside 43% of the 250 plus Zacks industries. Our analysis reveals that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
One different inventory from the identical business, HealthEquity (HQY), is but to report outcomes for the quarter ended October 2025. The outcomes are anticipated to be launched on December 3.
This supplier of companies for managing well being care accounts is anticipated to put up quarterly earnings of $0.90 per share in its upcoming report, which represents a year-over-year change of +15.4%. The consensus EPS estimate for the quarter has remained unchanged over the past 30 days.
HealthEquity’s revenues are anticipated to be $319.96 million, up 6.5% from the year-ago quarter.
Ought to You Put money into LifeMD, Inc. (LFMD)?
Earlier than you spend money on LifeMD, Inc. (LFMD), wish to know the perfect shares to purchase for the subsequent 30 days? Try Zacks Funding Analysis for our free report on the 7 greatest shares to purchase.
Zacks Funding Analysis has been dedicated to offering buyers with instruments and impartial analysis since 1978. For greater than 1 / 4 century, the Zacks Rank stock-rating system has greater than doubled the S&P 500 with a median achieve of +24.08% per yr. (These returns cowl a interval from January 1, 1988 by Might 6, 2024.)
LifeMD, Inc. (LFMD) : Free Inventory Evaluation Report
HealthEquity, Inc. (HQY) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
